NYRADA INC-CDI

0.490

-0.010-2.00%

Volume:37.64K

Turnover:18.86K

Market Cap:126.75M

PE:-17.86

High:0.505

Open:0.505

Low:0.490

Close:0.500

52wk High:1.435

52wk Low:0.295

Shares:258.68M

Float Shares:102.11M

Volume Ratio:1.15

T/O Rate:0.04%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.027

EPS(LYR):-0.027

ROE:-99.95%

ROA:-53.59%

PB:13.28

PE(LYR):-17.86

Loading ...

Overview Company News Filings

Nyrada Confirms Activation of First Site in Phase 2a Study of Drug Candidate for Heart Muscle Cell Damage

MT Newswires Live

·

Apr 22

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/NYR.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NYR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","market":"AU","secType":"STK","nameCN":"NYRADA INC-CDI","latestPrice":0.49,"timestamp":1791417662567,"preClose":0.5,"halted":0,"volume":37642,"delay":0,"changeRate":-0.020000000000000018,"nameEN":"NYRADA INC-CDI","floatShares":102113109,"shares":258681500,"eps":-0.02744,"marketStatus":"Trading","change":-0.01,"latestTime":"10-08 11:03:56 AEDT","open":0.505,"high":0.505,"low":0.49,"amount":18862,"amplitude":0.03,"askPrice":0.5,"askSize":1119,"bidPrice":0.49,"bidSize":10039,"shortable":3,"etf":0,"ttmEps":-0.02744,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1791435600000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.5,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":1.149881,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NYR.AU","preClose":0.525,"auctionPrice":0.545,"auctionVolume":4368,"auction":3,"marketStatus":"盘后竞价","timestamp":1791263399581}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NYR.AU\",,,,,undefined,":{"symbol":"NYR.AU","floatShares":102113109,"roa":"-53.59%","roe":"-99.95%","lyrEps":-0.02744,"volumeRatio":1.149881,"shares":258681500,"dividePrice":0,"high":0.505,"amplitude":0.03,"preClose":0.5,"low":0.49,"week52Low":0.295,"pbRate":"13.28","psRate":"63.02","week52High":1.435,"institutionHeld":0,"latestPrice":0.49,"committee":0.799426,"eps":-0.02744,"divideRate":0,"volume":37642,"delay":0,"ttmEps":-0.02744,"open":0.505,"prevYearClose":1.12,"prevWeekClose":0.52,"prevMonthClose":0.5,"prevQuarterClose":0.5,"fiveDayClose":0.5,"twentyDayClose":0.72,"sixtyDayClose":0.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NYR.AU\",params:#limit:5,,,undefined,":[{"date":"2023-07-28","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690502400000,"name":null,"time":"","dateTimestamp":1690466400000,"actualEps":null},{"date":"2023-04-29","symbol":"NYR.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1682726400000,"name":null,"time":"","dateTimestamp":1682690400000,"actualEps":null},{"market":"AU","date":"2022-08-29","symbol":"NYR.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1661695200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NYR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NYR.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2636898833","title":"Nyrada Inc-Xolatryp Enhances Anthracycline Anti-Tumour Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636898833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636898833?lang=en_us&edition=fundamental","pubTime":"2026-05-20 07:13","pubTimestamp":1779232439,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUE5F9DST:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636838375","title":"BRIEF-Nyrada Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2636838375","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636838375?lang=en_us&edition=fundamental","pubTime":"2026-05-19 14:54","pubTimestamp":1779173689,"startTime":"0","endTime":"0","summary":"BRIEF-Nyrada Seeks Trading Halt May 19 (Reuters) - Nyrada NYR.AX:TRADING HALT PENDING ANNOUNCEMENT ON PRE-CLINICAL ONCOLOGY STUDYFurther company coverage: NYR.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41V1IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NYR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636838398","title":"Nyrada Inc - Trading Halt Pending Announcement on Pre-Clinical Oncology Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2636838398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636838398?lang=en_us&edition=fundamental","pubTime":"2026-05-19 14:54","pubTimestamp":1779173667,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41V1IJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629109579","title":"Nyrada Confirms Activation of First Site in Phase 2a Study of Drug Candidate for Heart Muscle Cell Damage","url":"https://stock-news.laohu8.com/highlight/detail?id=2629109579","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629109579?lang=en_us&edition=fundamental","pubTime":"2026-04-22 11:52","pubTimestamp":1776829926,"startTime":"0","endTime":"0","summary":"Nyrada (ASX:NYR) confirmed that the Nepean Hospital in New South Wales was activated as the first site in its Protect-MI phase 2a clinical trial assessing Xolatryp in potentially reducing myocardial i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NYR.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":24,"code":"91000000","status":"200"}]}}